{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:28:35Z","timestamp":1787862515220,"version":"build-2784847793"},"reference-count":102,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment options are currently limited for persons with HIV\u20101 (PWH) who are heavily treatment\u2010experienced and\/or have multidrug\u2010resistant HIV\u20101. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment\u2010experienced and\/or have multidrug\u2010resistant HIV\u20101. In addition, future areas of research are also identified and discussed.<\/jats:p>","DOI":"10.1002\/phar.2914","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:34:45Z","timestamp":1717990485000},"page":"360-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Consensus recommendations for the use of novel antiretrovirals in persons with <scp>HIV<\/scp> who are heavily <scp>treatment\u2010experienced<\/scp> and\/or have <scp>multidrug\u2010resistant HIV<\/scp>\u20101: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-1144","authenticated-orcid":false,"given":"David B.","family":"Cluck","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy  Johnson City Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"additional","affiliation":[{"name":"University of Georgia College of Pharmacy  Albany Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-185X","authenticated-orcid":false,"given":"Milena","family":"Murray","sequence":"additional","affiliation":[{"name":"Midwestern University College of Pharmacy  Downers Grove Illinois USA"},{"name":"Northwestern Medicine  Evanston Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-3879","authenticated-orcid":false,"given":"Spencer H.","family":"Durham","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Auburn University Harrison College of Pharmacy  Auburn Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Palm Beach Atlantic University Gregory School of Pharmacy  West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-7965","authenticated-orcid":false,"given":"Caroline","family":"Derrick","sequence":"additional","affiliation":[{"name":"Prisma Health Midlands  Columbia South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-5819","authenticated-orcid":false,"given":"Julie B.","family":"Dumond","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-4224","authenticated-orcid":false,"given":"E. Kelly","family":"Hester","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Auburn University Harrison College of Pharmacy  Auburn Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Jeter","sequence":"additional","affiliation":[{"name":"University of Kentucky HealthCare  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-9460","authenticated-orcid":false,"given":"Melissa D.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Kilcrease","sequence":"additional","affiliation":[{"name":"HIV Prevention\/Treatment and Primary Care The Johns Hopkins Hospital, John G. Bartlett Specialty Practice  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-096X","authenticated-orcid":false,"given":"Wesley D.","family":"Kufel","sequence":"additional","affiliation":[{"name":"Binghamton University School of Pharmacy and Pharmaceutical Sciences  Binghamton New York USA"},{"name":"Division of Infectious Diseases State University of New York Upstate Medical University  Syracuse New York USA"},{"name":"State University of New York Upstate University Hospital  Syracuse New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kwong","sequence":"additional","affiliation":[{"name":"Division of Advanced Practice, School of Nursing Rutgers, The State University of New Jersey  Newark New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber F.","family":"Ladak","sequence":"additional","affiliation":[{"name":"Ryan White Program, Division of Infectious Disease Augusta University  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-549X","authenticated-orcid":false,"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Skaggs School of Pharmacy &amp; Pharmaceutical Sciences University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"HIV and Primary Care Ruth M. Rothstein CORE Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonell B.","family":"Poe","sequence":"additional","affiliation":[{"name":"Ryan White Program, Division of Infectious Disease Augusta University  Augusta Georgia USA"},{"name":"School of Allied Health Augusta University  Augusta Georgia USA"},{"name":"Department of Psychiatry, HIV\/LBTGQ Behavioral Track Augusta University  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-6557","authenticated-orcid":false,"given":"Charlotte","family":"Bolch","sequence":"additional","affiliation":[{"name":"Office of Research and Sponsored Programs Midwestern University  Glendale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Georgia  Athens Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Asiago\u2010Reddy","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases State University of New York Upstate Medical University  Syracuse New York USA"},{"name":"Inclusive Health Services State University of New York Upstate Medical University  Syracuse New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Short","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Perelman School of Medicine at the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"U.S. Department of Health and Human Services.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed July 1 2023.https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult\u2010and\u2010adolescent\u2010arv"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab583"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm522"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_2_10_7_1","unstructured":"Selzentry (maraviroc) Prescribing Information.Viiv Healthcare Company.2022https:\/\/dailymed.nlm.nih.gov\/dailymed\/getFile.cfm?setid=46f30ac5\u2010c96b\u2010429e\u2010976d\u20108c5ee1c0761b&type=pdf"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/507312"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_2_10_10_1","unstructured":"Trograzo (ibalizumab\u2010uiyk) Prescribing Information. Theratechnologies Inc.2022https:\/\/www.trogarzo.com\/assets\/pdfs\/THER\u2010TRO\u2010P437\u2010E%20Prescribing%20Information%20(2022).pdf"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_2_10_12_1","unstructured":"Rukobia (fostemsavir) Prescribing Information.ViiV Healthcare.2022https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Rukobia\/pdf\/RUKOBIA\u2010PI\u2010PIL.PDF"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_2_10_14_1","unstructured":"Sunlenca (lenacapavir) Prescribing Information. Gilead Sciences Inc.2022https:\/\/www.gilead.com\/\u2010\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf"},{"key":"e_1_2_10_15_1","volume-title":"RAND\/UCLA Appropriateness Method user's Manual","author":"Fitch K","year":"2000"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_10_18_1","unstructured":"Centers for Disease Control and Prevention.HIV and Youth. Accessed April 26 2023.https:\/\/www.cdc.gov\/hiv\/group\/age\/youth\/index.html"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1213"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.729"},{"key":"e_1_2_10_21_1","volume-title":"Ibalizumab efficacy and safety through 48\u2009weeks of treatment: results of an expanded access protocol (TMB\u2010311)","author":"Emu B","year":"2019"},{"key":"e_1_2_10_22_1","unstructured":"LeiderJMT LeeA MesquitaP McGaryC.Ibalizumab long\u2010term efficacy is not impacted by partially active antiretrovirals.24th Intl AIDS Conference.2022."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00992-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002591"},{"key":"e_1_2_10_25_1","volume-title":"Comparable efficacy of ibalizumab in combination with one or two fully active agents","author":"DeJesus EMC","year":"2020"},{"key":"e_1_2_10_26_1","volume-title":"Ibalizumab: 96\u2010week data and efficacy in patients resistant to common antiretrovirals","author":"Emu BLJ","year":"2019"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2172"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2171"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000594"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.09.010"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000002687"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13411"},{"issue":"30","key":"e_1_2_10_33_1","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV\u20101","volume":"4","author":"Wensing AM","year":"2022","journal-title":"Top Antivir Med"},{"key":"e_1_2_10_34_1","volume-title":"Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy versus IV administration","author":"Lin H\u2010H","year":"2017"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00942-08"},{"key":"e_1_2_10_36_1","unstructured":"KhanlouHGJ SchraderS TownerW WeinheimerS LewisS.Safety efficacy and pharmacokinetics of ibalizumab in treatment\u2010experienced HIV\u20101 infected patients: a phase 2b study.51st Interscience Conference on Antimicrobial Agents and Chemotherapy.2011."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000003097"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.552"},{"key":"e_1_2_10_39_1","volume-title":"IV push administration of ibalizumab: pharmacokinetics, safety, and efficacy","author":"DeJesus ERG","year":"2022"},{"key":"e_1_2_10_40_1","unstructured":"TaiMed Biologics Inc.Aaron Diamond AIDS Research Center Bill and Melinda Gates Foundation. Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers.2011\"Generic\"."},{"key":"e_1_2_10_41_1","unstructured":"Centers for Disease Control and Prevention.Contraception. Accessed July 26 2023.https:\/\/www.cdc.gov\/reproductivehealth\/contraception\/index.htm"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(20)30240-x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25187"},{"key":"e_1_2_10_44_1","first-page":"63","article-title":"Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment\u2010experienced adults with HIV\u20101: week 240 results of the phase III BRIGHTE study","volume":"25","author":"Aberg J","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_10_45_1","first-page":"S31","article-title":"Week\u201024 safety of fostemsavir in heavily treatment\u2010experienced participants with HIV\u20101 (study 205888, formerly AI438\u2010047)","volume":"19","author":"Kozal M","year":"2018","journal-title":"HIV Med"},{"key":"e_1_2_10_46_1","first-page":"S27","article-title":"Phase 3 study of fostemsavir in heavily treatment experienced HIV\u20101 infected subjects: day 8 and week 24 primary efficacy and safety results (study 205888, formerly AI438\u2010047)","volume":"19","author":"Kozal M","year":"2018","journal-title":"HIV Med"},{"key":"e_1_2_10_47_1","first-page":"1","article-title":"Week 96 safety and efficacy of the novel HIV\u20101 attachment inhibitor prodrug fostemsavir in heavily treatment\u2010experienced participants infected with multi\u2010drug resistant HIV\u20101 (BRIGHTE study)","volume":"22","author":"Lataillade M","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25187"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12814"},{"key":"e_1_2_10_50_1","unstructured":"LatailladeM LlamosoC PierceA et\u00a0al.Impact of susceptibility scoring on virologic response in heavily treatment\u2010experienced participants with HIV\u20101 receiving a fostemsavir\u2010based antiretroviral regimen: week 96 results from the randomized cohort of the phase 3 BRIGHTE study.17th European AIDS Conference.2019."},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1095"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13464"},{"key":"e_1_2_10_53_1","unstructured":"Department of Health and Human Services.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed April 1 2023.https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult\u2010and\u2010adolescent\u2010arv"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01751-21"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13183"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26009"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa474"},{"key":"e_1_2_10_58_1","first-page":"190","article-title":"Baseline and emergent genotypic and phenotypic results in HIV\u20101\u2010infected, heavily treatment\u2010experienced (HTE) participants meeting protocol\u2010defined virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHTE study","volume":"20","author":"Ackerman P","year":"2019","journal-title":"HIV Med"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000002851"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-021-00534-y"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(15)00177-0"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00513-13"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa073"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa178"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt018"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829726f3"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt412"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1810"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25187"},{"key":"e_1_2_10_70_1","article-title":"Fostemsavir exposure\u2010response relationships in treatment\u2010experienced HIV patients","author":"Parasrampuria R","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2021.2016301"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2178"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12763"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13442"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25616"},{"key":"e_1_2_10_76_1","first-page":"75","article-title":"Efficacy and safety of long\u2010acting subcutaneous lenacapavir in phase 2\/3 in heavily treatment\u2010experienced people with HIV: week 26 results (Capella study)","volume":"24","author":"Molina JM","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_10_77_1","first-page":"125","article-title":"Subgroup efficacy analyses of long\u2010acting subcutaneous lenacapavir in phase 2\/3 in heavily treatment\u2010experienced people with HIV (CAPELLA study)","volume":"22","author":"Stellbrink HJ","year":"2021","journal-title":"HIV Med"},{"key":"e_1_2_10_78_1","first-page":"26","article-title":"Long\u2010acting lenacapavir in people with multi\u2010drug resistant HIV\u20101: week 52 results","volume":"23","author":"Ogbuagu O","year":"2022","journal-title":"HIV Med"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.108"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(22)00291-0"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa060"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac364"},{"key":"e_1_2_10_84_1","first-page":"4","article-title":"Resistance analysis of long\u2010acting lenacapavir in highly treatment\u2010experienced people with HIV after 26\u2009weeks of treatment","volume":"22","author":"Margot N","year":"2021","journal-title":"HIV Med"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02057-20"},{"key":"e_1_2_10_86_1","volume-title":"Absence of cross\u2010resistance to lenacapavir in HIV entry inhibitor\u2010resistant isolates","author":"Margot N","year":"2022"},{"key":"e_1_2_10_87_1","volume-title":"Lenacapavir as part of a combination regimen in treatment na\u00efve PWH: week 54 results","author":"Gupta S","year":"2022"},{"key":"e_1_2_10_88_1","volume-title":"Pharmacokinetics of lenacapavir in participants with severe renal impairment","author":"Weber EJ","year":"2022"},{"key":"e_1_2_10_89_1","volume-title":"Pharmacokinetics of lenacapavir, an HIV\u20101 capsid inhibitor, in hepatic impairment","author":"Jogiraju V","year":"2021"},{"key":"e_1_2_10_90_1","volume-title":"Clinical evaluation of drug interactions with oral lenacapavir and probe drugs","author":"Begley R","year":"2021"},{"key":"e_1_2_10_91_1","unstructured":"BegleyRLJ RheeM Dvory\u2010SobolH et\u00a0al.GS\u20106207 sustained delivery formulation supports 6\u2010month dosing interval.23rd International AIDS Conference.2020."},{"key":"e_1_2_10_92_1","unstructured":"JogirajuVSM ShaikN BhaktaD et\u00a0al.Pharmacokinetic bridging with Oral Lenacapavir for missed subcutaneous Q6M dosing.12th IAS Conference on HIV Science.2023."},{"key":"e_1_2_10_93_1","unstructured":"OgbuaguOAA Segal\u2010MaurerS WangH et\u00a0al.Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered.12th IAS Conference on HIV Science. 2023."},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1086\/505356"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000214805.52723.c1"},{"key":"e_1_2_10_97_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).Human Immunodeficiency Virus\u20101 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry. Accessed April 21 2023.https:\/\/www.fda.gov\/files\/drugs\/published\/Human\u2010Immunodeficiency\u2010Virus\u20101\u2010Infection\u2010\u2010Developing\u2010Antiretroviral\u2010Drugs\u2010for\u2010Treatment.pdf"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.026"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab987"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.05.598"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002241"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9829-2"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:57:16Z","timestamp":1761062236000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/phar.2914"],"URL":"https:\/\/doi.org\/10.1002\/phar.2914","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}